X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising

By Holly Campbell  |    October 15, 2018
Pharmaceutical Research and Manufacturers of America (PhRMA) member companies today announced their commitment to providing more transparency about medicine costs to help patients make more...   Read More

Americans want to know more than just the list price of a medicine—and we’re answering their call

By Robert Zirkelbach  |    October 15, 2018
The biopharmaceutical industry is answering the call to provide more information about medicine costs. As innovators of life-saving therapies, we recognize the importance of giving people the...   Read More

Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles

By Katie Koziara  |    October 4, 2018
According to a new report by IQVIA Institute for Human Data Science, more and more patients are asked to pay high cost sharing due to changes in benefit design. Previous analysis has shown that...   Read More

Experts agree: the Bipartisan Budget Act changes to Medicare Part D jeopardize the program

By Juliet Johnson  |    September 24, 2018
The changes made to Part D in the Bipartisan Budget Act (BBA) that passed in February threaten the program’s successful competitive structure. While these changes closed the donut hole a year...   Read More

What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?

By Juliet Johnson  |    September 13, 2018
Right now, Congress has the opportunity to make two small fixes that will protect seniors in the Medicare Part D donut hole and save them money on out-of-pocket costs for their medicines.  These...   Read More

Number of value-based contracts continues to rise

By Michelle Drozd  |    August 27, 2018
The list of publicly announced value-based contracts (VBCs) – also called results-based contracts – between biopharmaceutical companies and health plans continued to grow over the last quarter –...   Read More

69 percent of patients abandon medicines when cost sharing is more than $250

By Holly Campbell  |    August 23, 2018
New research from the IQVIA Institute for Human Data Science shows that when cost sharing rises, patients are more likely to abandon their medicines. In 2017, 69 percent of commercially insured...   Read More

PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs

By Holly Campbell  |    July 16, 2018
Today, PhRMA submitted comprehensive comments to the Department of Health and Human Services (HHS) request for information (RFI), HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs....   Read More

New data show patients’ out-of-pocket costs are rising faster than their insurers’ costs

By Holly Campbell  |    July 9, 2018
Newly released data from the Kaiser Family Foundation show out-of-pocket costs for patients with employer-sponsored health insurance rose faster than the costs paid by their insurers between 2006...   Read More

Pass-through rebates do not violate non-interference clause but they do increase savings for seniors

By Jim C. Stansel  |    July 2, 2018
For more than a decade, Medicare Part D has successfully provided seniors with comprehensive prescription drug coverage. Key to its success is a unique, market-based structure of private-sector...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates